FATEライブシグナル | Getagraph.comで利益を最大化

買う 107767 min ago

@ $6.43

発行日: 15 2月 2024 @ 05:38

リターン: -35.77%

前回のシグナル: 2月 15 - 03:20

前回のシグナル: 売る

リターン: -1.30 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide...

Stats
本日の出来高	1.69M
平均出来高	2.72M
時価総額	470.06M
EPS	$0 ( 2024-02-26 )
次の収益日	( $-0.480 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.52
ATR14	$0.0110 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Redmile Group, Llc	Buy	3 636 364	Pre-Funded Warrants to Purchase Common Stock
2024-03-04	Dulac Edward J Iii	Sell	2 447	Common Stock
2024-02-01	Wolchko J Scott	Buy	500 000	Stock Option (Right to Buy)
2024-02-01	Tahl Cindy	Buy	425 000	Stock Option (Right to Buy)
2024-02-01	Dulac Edward J Iii	Buy	425 000	Stock Option (Right to Buy)

INSIDER POWER
40.61
Last 99 transactions
Buy: 17 254 718 \| Sell: 8 388 589

ボリューム相関

長: 0.00 (neutral)

短: -0.35 (neutral)

Signal:(78.695) Neutral

Fate Therapeutics Inc 相関

10 最も正の相関
STRC	0.974
ONCS	0.971
WISA	0.97
TTCF	0.969
IMRX	0.968
LUMO	0.964
GROM	0.961
VIRX	0.957
IMCC	0.956
MEDS	0.956

10 最も負の相関
NWFL	-0.96
IBEX	-0.95
MNKD	-0.947
PWOD	-0.942
LRFC	-0.935
HZNP	-0.934
XOMAO	-0.931
PDD	-0.931
IMMR	-0.93
ISIG	-0.93

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Fate Therapeutics Inc 相関 - 通貨/商品

0.51
( weak )

0.41
( neutral )

0.00
( neutral )

0.77
( moderate )

0.47
( neutral )

-0.63
( weak negative )

Fate Therapeutics Inc 財務諸表

Annual	2023
収益:	$63.53M
総利益:	$45.25M (71.22 %)
EPS:	$-1.640

FY	2023
収益:	$63.53M
総利益:	$45.25M (71.22 %)
EPS:	$-1.640

FY	2022
収益:	$96.30M
総利益:	$82.54M (85.71 %)
EPS:	$-2.63

FY	2021
収益:	$55.85M
総利益:	$55.85M (100.00 %)
EPS:	$-2.24

Financial Reports:

No articles found.

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

リアルタイムの更新： Fate Therapeutics Inc [FATE]

Upcoming Earnings Alert